Hodgkin lymphoma is becoming more treatable than ever. A new review of the latest research shows that for early-stage patients, the 5-year survival rate now exceeds 90%. For those with advanced disease, long-term remission rates are above 75%.
The review looked at modern treatments including brentuximab vedotin and PD-1 inhibitors. These drugs are changing how doctors approach the disease. But the picture isn't all rosy. About 5% to 10% of patients have disease that doesn't respond to initial treatment, and 10% to 30% will eventually relapse.
There's also a cost to these successes. Long-term toxicities from treatment can include secondary cancers, heart disease, lung scarring, and infertility. That's why researchers are now focusing on de-escalating therapy when possible and using precision medicine to tailor treatments.
This review summarizes a shift in thinking: how to cure more people while reducing the lasting harm of treatment. It's a hopeful but cautious update for anyone affected by Hodgkin lymphoma.